… abnormalities in this experiment. Preliminary data from the biochemical assessments of a-synuclein in different brain regions from the experimental mice suggest that NP003 impacted … mice administered the drug vs. vehicle. Although the data from this study are pilot in nature utilizing very small …

… Parkinson’s disease. We look forward to reporting results from our ongoing Phase 1 multiple ascending dose study of … Foundation has supported research in Parkinson’s biomarkers from its earliest days and leads the landmark observational … disease-causing synuclein can be propagated and transmitted from neuron to neuron, resulting in an infection-like spread …

… Manager, you will: Design data flow in cohort studies from data collection to distribution sourcing feedback from study leadership and informatics groups Develop, … and user experience for technologies ranging from mature to alpha stages Advocate for the user by leading …

… This grant builds upon the research from a prior grant: CDNF a novel conserved neurotrophic … of the neurorestorative effect of CDNF is very different from that of GDNF. Another important difference is that the … Parkinson’s disease. This project led to follow-on funding from the Academy of Finland. This funding is for research …

… nerve and not in the substantia nigra of the midbrain. From the brainstorm, the pathological process appears to … lining of the gut, i.e., the body's innermost environment. From there, the disease process could reach the brain via … study included examination of brain and stomach tissues from 150 autopsy cases. Of these, the brains of 120 cases …

… This grant builds upon the research from a prior grant: Delivery of GDNF to the Brain by Novel … determining the rate of elimination of the delivered GDNF from the striatum. Then, using a treatment regimen that will … cells in the substantia nigra. These beneficial effects from the encapsulated GDNF indicate the potential of our …